“To develop the company’s presence on foreign markets, in the first half of 2013 we have analyzed the possibility of opening company branches to promote our products and generate a larger volume of consumption and sales and to consolidate the company’s image,” the company said in a report Wednesday, adding it has started promotion activities in the Republic of Moldova.
Countries analyzed for the opening of offices are Poland, Czech Republic, Slovakia, Ukraine, Kazakhstan, Uzbekistan, Serbia, Macedonia, Bosnia, and Montenegro.
The company said in its report the European market is a top priority and it has negotiated and started access projects for its products in the first half of 2013 and estimates a rise in exports on EU markets. Another important market for Antibiotice is the U.S., where it has recently launched a new product and where it expects a raise in sales by over $2.5 million.
The company added it has projects underway targeting Germany, France, and Brazil.
Antibiotice Iasi exports finite pharmaceuticals and active substances in 60 countries worldwide, via over 100 partners.
Antibiotice’s sales declined 4% in the first half of the year, to RON141.8 million (EUR32.3 million), and its net profit dropped 37%, to RON16.1 million (EUR3.6 million). The company said exports rose over 30% year-on-year to RON43.7 million (EUR10 million), from RON33.6 million from the same period in 2012.